Evaluation of socio-demographic characteristics of people was determined to use synthetic cannabinoids in Malatya and its surrounding cities / districts and LC-MS/MS analysis method

Aim: Synthetic cannabinoids (SC) were initially developed in 1960s to target the cannabinoid receptors in medical therapy. However, in recent years, the developed SC derivatives by processing the plant-based material have been sold on websites under the name of natural drugs. The city of Malatya is located at the eastern part of Turkey and has an important location for the transfer and marketing of narcotic substances. In our study, presentation of the socio-demographic characteristics of the cases, the SC was determined in whose blood samples in the analyses, living in Malatya and the surrounding cities-districts were aimed. Materials and Methods: In the scope of study, 275 cases whose blood samples was sent to the Chemistry Department in Forensic Medicine Institute at Malatya Group Presidency in 2016 and were detected as SC-positive by the chemical analysis were investigated. Results: Out of 275 cases, 97.8% were male, 2.2% were female. Median age was 24, 66.5% (n=180) of them were primary school, 18% (n=51) were high school graduate and 0.7% (n=2) were university graduate. The educational status of 27 cases could not be obtained. Conclusion: SC derivatives are marketed with slogan of “the natural ones are harmless”, and their use among the young people is rapidly becoming widespread. In our study, it was determined that the SC users are in the young age group and have low educational status. In order to decrease the number of users, awareness meetings regarding the harmful effects of SC must be organized in the educational institutions.

PDF

___

1. Young AC, Schwarz E, Medina G, et al. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med 2012;30:5-7.
2. Huffman JW, Dai D, Martin BR, et al. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg Med Chem Lett 1994;4:563-6.
3. Atik SU, Dedeoglu R, Varol F, et al. Cardiovascular side effects related with use of synthetic cannabinoids “bonzai”: two case reports. Türk Ped Arş 2015;50:61- 4.
4. Debruyne D, Boisselier R. Emerging drugs of abuse: current perspectives on synthetic cannabinoids. Substance Abuse and Rehabilitation 2015;6:113-29.
5. Tait RJ, Caldicott D, Mountain D, et al. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clinical Toxicology 2016;54:1-13.
6. Von der Haar J, Talebi S, Ghobadi F, et al. Synthetic cannabinoids and their effects on the cardiovascular system. J Emerg Med 2016;50:258-62.
7. European Drug Report Trends and Developments, http://www.emcdda.europa.eu/system/files/ publications/2637/TDAT16001TRN.pdf (2016, accessed 10 September 2018).
8. Turkey Drug Report, http://eos.aeo.org.tr/userfiles/ files/230_2014-Turkiye-Uyusturucu-RaporuHakkinda.pdf (2014, accessed 10 September 2018).
9. Cannaert A, Storme J, Franz F, et al. Detection and activity profiling of synthetic cannabinoids and their metabolites with a newly developed bioassay. Anal Chem 2016;88:11476−85.
10. Cooper ZD. Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal. Curr Psychiatry Rep 2016;18:52.
11. Mir A, Obafemi A, Young A, et al. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 2011;128:1622-7.
12. Tournebize J, Gibaja V, Kahn JP. Acute effects of synthetic cannabinoids: Update 2015. Substance Abuse 2016;11:1-23.
13. White C. M. The pharmacologic and clinical effects of illicit synthetic cannabinoids. The Journal of Clinical Pharmacology 2017;57:297-304.
14. Su MK, Seely KA, Moran JH, et al. Metabolism of classical cannabinoids and the synthetic cannabinoid JWH-018. Int J Clin Pharmacol Ther 2015;97:562-4.
15. Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 2011;50:193-211.
16. Gatch MB, Forster MJ. Δ9-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids found on the gray market. Behav Pharmacol 2015;26:460-8.
17. Jang M, Shin I, Yang W, et al. Determination of major metabolites of MAM 2201 and JWH-122 in in vitro and in vivo studies to distinguish their intake. Forensic Sci Int 2014;244:85-91.
18. Zaitsu K, Hayashi Y, Suzuki K, et al. Metabolome disruption of the rat cerebrum induced by the acute toxic effects of the synthetic cannabinoid MAM 2201. Life Sciences 2015;137:49-55.
19. Ministerial Committee Decision published in the official gazette dated 13 February 2011, numbered 27845, decision numbered 2011/1310, http://www. resmigazete.gov.tr/eskiler/2011/02/20110213-4.htm (2011, accessed 10 September 2018).
20. Ministerial Committee Decision published in the official gazette dated 23 May 2014, numbered 29008, decision numbered 2014/6330, http://www.resmigazete. gov.tr/eskiler/2014/05/20140523M1-31.htm (2014, accessed 10 September 2018).
21. Center for Behavioural Health Statistics and Quality. The DAWN Report: Drug-Related Emergency Department Visits Involving Synthetic Cannabinoids, http://archive.samhsa.gov/data/2k12/DAWN105/ SR105-syntheticmarijuana.pdf (2012 accessed 10 September 2018).
22. Ozturk YE, Yeter O, Alpertunga B. Validation of JWH018 and its metabolites in blood and urine by UPLC– MS/MS: Monitoring in forensic cases. Forensic Science International 2015;248:88-93.